washington  reuters    president donald trump on monday said he is nominating former pharmaceutical executive and industry lobbyist alex azar to serve as u s  health and human services secretary  saying azar would push to lower the price of medicines  republicans as well as the lead lobby groups for drugmakers and health insurers welcomed azar as an experienced hand who could help overhaul the world s most costly healthcare system   but several democratic lawmakers questioned whether he would tackle changes that cut into pharmaceutical profits  if confirmed  azar also would take the lead in implementing trump s campaign promise to dismantle the affordable care act  former democratic president barack obama s  healthcare overhaul that extended health insurance to  million americans  democratic representative elijah cummings said trump s pick of a former pharmaceutical executive was  like a fox guarding the hen house   trump  who is in the philippines on a diplomatic trip  announced the nomination on twitter by saying azar would  be a star for better healthcare and lower drug prices   trump s first health secretary  former u s  representative tom price  resigned in september amid a public furor over his use of expensive taxpayer funded private charter jets for government travel    azar worked at eli lilly  lly n  and co for a decade  including five years as president of its lilly usa unit  and left the company in january  according to his linkedin page   cummings and senator bernie sanders  a  democratic presidential candidate  last year called for a federal probe into whether eli lilly  sanofi sa  sasy pa   merck   co inc  mrk n  and novo nordisk a s  novob co  colluded to set prices on insulin and other diabetes drugs   this is a slap in the face to millions of americans who are waiting on  the president  to take action to lower drug prices   cummings wrote on twitter  he also pointed to eli lilly raising drug prices by double digits while azar was an executive at the company  azar  though a spokesman  declined to comment  other democrats were more cautious in their response to trump s announcement  with senator chuck schumer calling for the health agency to turn over a new leaf with azar  democratic senator patty murray  who has been working on bipartisan healthcare legislation  tweeted   given alex azar s professional background  there are concerns on whether he can fairly execute any significant effort to lower drug prices for patients   families   republicans were supportive with senate health committee head lamar alexander of tennessee describing azar as a qualified  experienced nominee  azar also drew praise from phrma  the largest pharmaceutical industry trade group and america s health insurance plans  the key lobbyist for the insurer industry  azar served several years on the board of directors of the biotechnology innovation organization  a drug industry lobbying group  and earlier was general counsel and deputy secretary for health and human services under former republican president george w  bush  patient advocacy organization public citizen said azar has made it clear he is opposed to measures  to restrain prescription companies  profiteering and limit improper marketing  and that he favors weaker safety approval standards  as head of hhs  azar would have oversight responsibility for the u s  food and drug administration  which regulates the drug industry including approving new treatments        azar s nomination must be approved by the u s  senate  which is controlled by trump s fellow republicans  